Clinical trial NCT02701803: Parkinson's KinetiGraph, PKG in Patients With Deep Brain Stimulation and Continuous Levodopa Infusion Therapy
Official title: Ambulatory Movement Registration in Patients With Deep Brain Stimulation and Continuous Intraduodenal Levodopa Therapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parkinson's Disease
Lead sponsor: Hospital District of Helsinki and Uusimaa
Sponsor class: OTHER
First posted: 2016-03-08
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Study population is consisted of patients with advanced Parkinson's disease in HUH neurological clinic. The treatment decision of deep brain stimulation and/or continuous intraduodenal levodopa therapy is done clinically by the treating physician. The patients are enrolled in the study after the clinical decision is made.

Brief summary: In this study the aim is to evaluate the outcome of deep brain stimulation (DBS) and continuous intraduodenal levodopa therapy in patients with advanced Parkinson' disease by using Parkinson's KinetiGraph™ device which is a movement and acceleration measuring device. In this study we also evaluate the usability of Parkinson's KinetiGraph™ device by comparing it with written patient diaries.

Detailed description: In this study the aim is to evaluate the outcome of deep brain stimulation (DBS) and continuous intraduodenal levodopa therapy in patients with advanced Parkinson' disease by using Parkinson's KinetiGraph™ logger (PKG) device which is a movement and acceleration measuring device.

A measurement is done before and after the implantation of selected therapy. PKG will measure automatically in every two minutes the movement of selected limb (usually the more affected upper extremity) for six days. At the same time a patient will keep a written diary of his/her Parkinsonian symptoms. Diary and collected PKG data will be compared. PKG will also remind with vibration the patient of the time drug administration and the patient can confirm this with pressing a button on PKG. The collected data will be transmitted to a computer and analyzed mathematically to produce a visual graph of daily movements. The aim is to evaluate PKG's usability in measuring Parkinsonian symptoms and in evaluation the outcome of DBS and levodopa therapy. Main parameters in evaluation are bradykinesia score and dyskinesia score.

Eligibility criteria: Inclusion Criteria:

* Patient with diagnosed Parkinson's disease
* Parkinson's disease is in advanced state (defined by the treating physician)
* A good response with over 30 % improvement of scores in Unified Parkinson's disease rating scale part III in pre-DBS evaluation

Exclusion Criteria:

* Age older than 70 years (this is a clinical exclusion criteria for DBS treatment)
* No history of psychosis or depression (this is a clinical exclusion criteria for DBS and intraduodenal levodopa therapy)
* No diagnosed dementia (this is a clinical exclusion criteria for DBS and intraduodenal levodopa therapy)

Primary outcomes:
measure: Bradykinesia score
timeFrame: 6 months
Secondary outcomes:
measure: Dyskinesia score
timeFrame: 6 months
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: HUH Meilahti Hospital, department of neurology
Study officials:
affiliation: HUH, Meilahti Hospital, department of neurology
name: Eero Pekkonen, M.D., Ph.D.
role: STUDY_DIRECTOR
References: